|
| 唑来膦酸治疗绝经后骨质疏松急性期不良反应影响因 素的相关分析 |
| Correlation analysis of the influential factors of acute phase response after intravenous zoledronic acid treatment for postmenopausal osteoporosis |
| |
| DOI： |
| 中文关键词: 急性期不良反应 唑来膦酸 影响因素 绝经后骨质疏松 |
| 英文关键词:Acute phase response Zoledronic acid Factors Postmenopausal osteoporosis. |
| 基金项目: |
|
| 摘要点击次数: 1075 |
| 全文下载次数: 1121 |
| 中文摘要: |
| 目的探讨唑来膦酸静脉注射治疗绝经后骨质疏松症出现急性期不良反应（APR)情况及可能的影响因素。方法分 析2012年8月-2013年6月期间我院内分泌科、骨科应用唑来膦酸治疗绝经后骨质疏松症的患者107例，均应用唑来膦酸 5 mg静脉注射。分为发生APR组[APR( + )]及未发生APR组[APR( -)]，比较两组之间年龄、BMI、是否曾服用钙片、非甾 体类消炎药(NSAIDs)、双膦酸盐等因素与APR的相关性。结果（1)107例患者中总不良反应发生率为83.2% ;其中发热78 例("72. 9% );肌肉痛51例(47 7% );发热和胃肠道反应2例（1. 9%);(2) APR( + )组BMI水平、曾使用双膦酸盐比例低于 APR(-)组(P <0. 05)，合并骨质疏松性骨折比例高于APR(-)组(P <0. 05);(3) Logistic回归分析显示BMI和使用双膦酸 盐为APR的发生的保护因素(P <0.05)。结论唑来膦酸（5mg)静脉注射后急性期不良反应较常见，多为一过性。高BMI 及曾使用双膦酸盐可减少急性期不良反应发生的风险。 |
| 英文摘要: |
| Objective To investigate the characteristics of the acute phase response (APR) after intravenous zoledronic acid treatment for postmenopausal osteoporosis and the potential factors of the APR development. Methods A total of 107 patients with postmenopausal osteoporosis，who were treated in the Department of Endocrinology and the Department of Orthopedics from August 2012 to June 2013，were selected. All the patients were treated with 5 mg zoledronic acid intravenously，and they were divided into with APR group [ APR ( +)] or without APR group [ APR ( - )]. The difference of age，BMI，calcium intake，NSAIDs intake，and previous treatment with bisphosphonate was compared between the two groups . And the correlation analysis was also performed. Results The total rate of APR in 107 patients was 83. 2%. Among which，78 patients experienced fever (72. 9% ); 51 patients had musculoskeletal pain (47. 7% ) ； and 2 patients suffered from fever and gastrointestinal reaction (1. 9% ). BMI and the rate of bisphosphonate history in APR ( + ) group were lower than those in APR ( -) group (P < 0. 05)，while the rate of osteoporotic fracture in APR ( + ) group was higher than that in APR ( - ) group (P < 0. 05). Logistic regression analysis suggested that BMI and previous treatment with bisphosphonate were protective factors of the development of APR (P < 0. 05). Conclusion After intravenous injection of 5mg zoledronic acid， APR occurs frequently， but transiently. Higher BMI and previous treatment with bisphosphonate significantly reduce the risk of APR . |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |